{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:18:50Z","timestamp":1788445130135,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012171","name":"Ontario Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mathematical Biosciences"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.mbs.2026.109763","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:40:16Z","timestamp":1783600816000},"page":"109763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A delay differential model for antiviral treatment and rebound dynamics"],"prefix":"10.1016","volume":"400","author":[{"given":"Wenben","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-0227","authenticated-orcid":false,"given":"Seyed M.","family":"Moghadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0052-5336","authenticated-orcid":false,"given":"Jianhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mbs.2026.109763_bib0001","doi-asserted-by":"crossref","unstructured":"E. Mahase, COVID-19: Pfizer\u2019s Paxlovid is 89% effective in patients at risk of serious illness, company reports, BMJ 375(2021) n2713.","DOI":"10.1136\/bmj.n2713"},{"issue":"5","key":"10.1016\/j.mbs.2026.109763_bib0002","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2473","article-title":"Efficacy and safety of Paxlovid (nirmatrelvir\/ritonavir) in the treatment of COVID-19: an updated meta-analysis and trial sequential analysis","volume":"33","author":"Tian","year":"2023","journal-title":"Rev. Med. Virol."},{"issue":"1","key":"10.1016\/j.mbs.2026.109763_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004493","article-title":"Effect of nirmatrelvir\/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: an electronic health record-based target trial emulation from N3C","volume":"22","author":"Bhatia","year":"2025","journal-title":"PLoS Med."},{"issue":"6575","key":"10.1016\/j.mbs.2026.109763_bib0004","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.mbs.2026.109763_bib0005","doi-asserted-by":"crossref","DOI":"10.1038\/d41586-022-02121-z","article-title":"COVID rebound is surprisingly common-even without Paxlovid","author":"Callaway","year":"2022","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.mbs.2026.109763_bib0006","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMc2206449","article-title":"Rebound of SARS-CoV-2 infection after nirmatrelvir\u2013ritonavir treatment","volume":"387","author":"Charness","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.mbs.2026.109763_bib0007","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1093\/cid\/ciac512","article-title":"Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for coronavirus disease 2019 (COVID-19)","volume":"76","author":"Boucau","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.mbs.2026.109763_bib0008","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1038\/s41467-024-49458-9","article-title":"A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy","volume":"15","author":"Esmaeili","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.mbs.2026.109763_bib0009","doi-asserted-by":"crossref","first-page":"e01623","DOI":"10.1128\/jvi.01623-24","article-title":"Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance","volume":"99","author":"Phan","year":"2025","journal-title":"J. Virol."},{"issue":"47","key":"10.1016\/j.mbs.2026.109763_bib0010","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc7112","article-title":"Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response","volume":"6","author":"Goyal","year":"2020","journal-title":"Sci. Adv."},{"issue":"49","key":"10.1016\/j.mbs.2026.109763_bib0011","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111477118","article-title":"In vivo kinetics of SARS-CoV-2 infection and its relationship with a person\u2019s infectiousness","volume":"118","author":"Ke","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mbs.2026.109763_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbs.2024.109339","article-title":"A theory for viral rebound after antiviral treatment: a study case for SARS-CoV-2","volume":"379","author":"Perez","year":"2025","journal-title":"Math. Biosci."},{"key":"10.1016\/j.mbs.2026.109763_bib0013","series-title":"Mathematical Epidemiology of Infectious Diseases: Model Building, Analysis and Interpretation","volume":"Vol. 5","author":"Diekmann","year":"2000"},{"issue":"1-2","key":"10.1016\/j.mbs.2026.109763_bib0014","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-5564(02)00108-6","article-title":"Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission","volume":"180","author":"Van den Driessche","year":"2002","journal-title":"Math. Biosci."},{"issue":"3","key":"10.1016\/j.mbs.2026.109763_bib0015","first-page":"288","article-title":"Reproduction numbers of infectious disease models","volume":"2","author":"Van den Driessche","year":"2017","journal-title":"Infect. Dis. Model."},{"issue":"30","key":"10.1016\/j.mbs.2026.109763_bib0016","doi-asserted-by":"crossref","first-page":"17513","DOI":"10.1073\/pnas.2008373117","article-title":"The implications of silent transmission for the control of COVID-19 outbreaks","volume":"117","author":"Moghadas","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mbs.2026.109763_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100865","article-title":"Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants","volume":"35","author":"Sah","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"34","key":"10.1016\/j.mbs.2026.109763_bib0018","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109229118","article-title":"Asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis","volume":"118","author":"Sah","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"51","key":"10.1016\/j.mbs.2026.109763_bib0019","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000036714","article-title":"Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: a non-randomized controlled clinical trial","volume":"102","author":"Xu","year":"2023","journal-title":"Medicine"},{"key":"10.1016\/j.mbs.2026.109763_bib0020","article-title":"An explanation for SARS-CoV-2 rebound after Paxlovid treatment","author":"Perelson","year":"2023","journal-title":"MedRxiv"},{"key":"10.1016\/j.mbs.2026.109763_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2023.04.318","article-title":"Rebound COVID-19 after Paxlovid in 2 related family members","volume":"130","author":"Periyasamy","year":"2023","journal-title":"Int. J. Infect. Dis."},{"issue":"12","key":"10.1016\/j.mbs.2026.109763_bib0022","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.7326\/M23-1756","article-title":"SARS-CoV-2 virologic rebound with nirmatrelvir\u2013ritonavir therapy: an observational study","volume":"176","author":"Edelstein","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.mbs.2026.109763_bib0023","unstructured":"CDC Health Advisory: COVID-19 rebound after Paxlovid treatment, CDCHAN-0467 (2022) 1\u20134."},{"issue":"3","key":"10.1016\/j.mbs.2026.109763_bib0024","article-title":"Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19)","volume":"2","author":"Gomes","year":"2020","journal-title":"Braz. J. Implantol. Health Sci."},{"issue":"1","key":"10.1016\/j.mbs.2026.109763_bib0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/M22-2141","article-title":"Nirmatrelvir plus ritonavir for early COVID-19 in a large US health system: a population-based cohort study","volume":"176","author":"Dryden-Peterson","year":"2023","journal-title":"Ann. Intern. Med."},{"issue":"9","key":"10.1016\/j.mbs.2026.109763_bib0026","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35431","article-title":"Emerging SARS-CoV-2 resistance after antiviral treatment","volume":"7","author":"Tamura","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.mbs.2026.109763_bib0027","doi-asserted-by":"crossref","first-page":"7999","DOI":"10.1038\/s41467-024-51924-3","article-title":"Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections","volume":"15","author":"Nooruzzaman","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Mathematical Biosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025556426001537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025556426001537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:59:31Z","timestamp":1788443971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025556426001537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":27,"alternative-id":["S0025556426001537"],"URL":"https:\/\/doi.org\/10.1016\/j.mbs.2026.109763","relation":{},"ISSN":["0025-5564"],"issn-type":[{"value":"0025-5564","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A delay differential model for antiviral treatment and rebound dynamics","name":"articletitle","label":"Article Title"},{"value":"Mathematical Biosciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mbs.2026.109763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109763"}}